Table 2.
Novel immune checkpoint inhibitors in HCC.
| Drug | Target | NCT number | Phase | Settings | Treatment arms |
|---|---|---|---|---|---|
| Relatlimab | LAG-3 | NCT04658147 | I | Hepatocellular carcinoma | Nivolumab; Nivolumab + Relatlimab |
| SRF388 | LAG-3 | NCT04374877 | I | Advanced solid tumor | SRF388; SRF388 + Pembrolizumab |
| Relatlimab | LAG-3 | NCT04567615 | II | Liver cancer | Nivolumab; Nivolumab + Relatlimab |
| INCAGN02385 | LAG-3 | NCT03538028 | I | Advanced solid tumor | INCAGN02385 |
| Relatlimab | LAG-3 | NCT02465060 | II | Advanced solid tumor | Relatlimab |
| Pavunalimab | CTLA-4 and LAG-3 | NCT03849469 | I | Advanced solid tumor | Pavunalimab; Pavunalimab + Pembrolizumab |
| Cobolimab | TIM-3 | NCT03680508 | II | Liver cancer | Dostarlimab + Cobolimab |
| INCAGN02390 | TIM-3 | NCT03652077 | I | Advanced solid tumor | INCAGN02390 |
| KY1044 | ICOS | NCT03829501 | I and II | Advanced solid tumor | KY1044; KY1044 + Atezolizumab |